APPL1

Across TCGA pan-cancer cohorts, APPL1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated APPL1 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher APPL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated APPL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where APPL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.847	0.677	.001	30	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	20	view →
LUAD	DFS	Median	All	0.738	0.492	.015	9	view →
HNSC	DFS	Quartile	IV	0.795	0.538	.037	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

APPL1–PDAC (DFS)

Open the PDAC breakdown →